[HTML][HTML] Management and treatment of hepatocellular carcinoma with immunotherapy: a review of current and future options
With mortality rates of liver cancer doubling in the last 20 years, this disease is on the rise
and has become the fifth most common cancer in men and the seventh most common …
and has become the fifth most common cancer in men and the seventh most common …
[HTML][HTML] Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
DS Mandlik, SK Mandlik… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors,
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …
[HTML][HTML] Immunotherapy for hepatocellular carcinoma: current and future
MP Johnston, SI Khakoo - World journal of gastroenterology, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) arises on the background of chronic liver disease. Despite
the development of effective anti-viral therapeutics HCC is continuing to rise, in part driven …
the development of effective anti-viral therapeutics HCC is continuing to rise, in part driven …
Immunotherapy for hepatocellular carcinoma: recent advances and future targets
SJ Yu - Pharmacology & Therapeutics, 2023 - Elsevier
Immunotherapy is a promising approach to treating various types of cancers, including
hepatocellular carcinoma (HCC). While single immunotherapy drugs show limited …
hepatocellular carcinoma (HCC). While single immunotherapy drugs show limited …
[HTML][HTML] Immunotherapy for hepatocellular carcinoma: From basic research to clinical use
Hepatocellular carcinoma (HCC) is a common cancer worldwide with a poor prognosis. Few
strategies have been proven efficient in HCC treatment, particularly for those patients not …
strategies have been proven efficient in HCC treatment, particularly for those patients not …
[HTML][HTML] Advances in immunotherapy for hepatocellular carcinoma
B Sangro, P Sarobe, S Hervás-Stubbs… - Nature reviews …, 2021 - nature.com
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
[HTML][HTML] Immunotherapy in hepatocellular carcinoma
Opinion statement Patients with hepatocellular carcinoma (HCC) have been traditionally
deprived from highly effective systemic therapy options in the past decades. The multi …
deprived from highly effective systemic therapy options in the past decades. The multi …
[HTML][HTML] Potentiality of immunotherapy against hepatocellular carcinoma
N Tsuchiya, Y Sawada, I Endo, Y Uemura… - World Journal of …, 2015 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the fifth
most common cancer worldwide and the second leading cause of cancer-related death …
most common cancer worldwide and the second leading cause of cancer-related death …
[HTML][HTML] Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
J Li, S Xuan, P Dong, Z Xiang, C Gao, M Li… - Frontiers in …, 2023 - frontiersin.org
Due to its widespread occurrence and high mortality rate, hepatocellular carcinoma (HCC) is
an abhorrent kind of cancer. Immunotherapy is a hot spot in the field of cancer treatment …
an abhorrent kind of cancer. Immunotherapy is a hot spot in the field of cancer treatment …
Recent advances in immunotherapy for hepatocellular carcinoma
AA Khan, ZK Liu, X Xu - Hepatobiliary & Pancreatic Diseases International, 2021 - Elsevier
Background Treatment of hepatocellular carcinoma (HCC) is challenging as most patients
are diagnosed at advanced stage with underlying chronic liver conditions. Conventional …
are diagnosed at advanced stage with underlying chronic liver conditions. Conventional …